COLLPLANT BIOTECH. IS-01 (CPT) - Total Liabilities
Based on the latest financial reports, COLLPLANT BIOTECH. IS-01 (CPT) has total liabilities worth €4.70 Million EUR (≈ $5.50 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of COLLPLANT BIOTECH. IS-01 to track the company's year-over-year net asset growth rate.
COLLPLANT BIOTECH. IS-01 - Total Liabilities Trend (2021–2025)
This chart illustrates how COLLPLANT BIOTECH. IS-01's total liabilities have evolved over time, based on quarterly financial data. See CPT free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
COLLPLANT BIOTECH. IS-01 Competitors by Total Liabilities
The table below lists competitors of COLLPLANT BIOTECH. IS-01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gratomic Inc
V:GRAT
|
Canada | CA$7.10 Million |
|
Sonim Technologies Inc
NASDAQ:SONM
|
USA | $50.62 Million |
|
Bank Maybank Indonesia Tbk PT
JK:BNII
|
Indonesia | Rp160.63 Trillion |
|
Lomiko Metals Inc
V:LMR
|
Canada | CA$3.57 Million |
|
Binani Industries Limited
NSE:BINANIIND
|
India | Rs2.02 Billion |
|
MOVIE GAMES S.A. ZY1
F:2LH
|
Germany | €5.65 Million |
|
Dunedin Income Growth Investment Trust PLC
LSE:DIG
|
UK | GBX50.01 Million |
|
Munic SA
PA:ALMUN
|
France | €7.13 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down COLLPLANT BIOTECH. IS-01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is COLLPLANT BIOTECH. IS-01 worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how COLLPLANT BIOTECH. IS-01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for COLLPLANT BIOTECH. IS-01 (2021–2025)
The table below shows the annual total liabilities of COLLPLANT BIOTECH. IS-01 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €4.70 Million ≈ $5.50 Million |
-10.31% |
| 2024-12-31 | €5.25 Million ≈ $6.13 Million |
-9.35% |
| 2023-12-31 | €5.79 Million ≈ $6.76 Million |
+5.45% |
| 2022-12-31 | €5.49 Million ≈ $6.41 Million |
-10.09% |
| 2021-12-31 | €6.10 Million ≈ $7.14 Million |
-- |
About COLLPLANT BIOTECH. IS-01
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal a… Read more